Literature DB >> 19327567

Screening, surveillance, and prevention for esophageal cancer.

Yutaka Tomizawa1, Kenneth K Wang.   

Abstract

The incidence of esophageal cancer, especially esophageal adenocarcinoma, is increasing and its high mortality rate is a notable fact. Improving survival rates of this disease depend on earlier detection through screening and surveillance; however, standard diagnostic modalities, such as endoscopy with biopsy, have several limitations as screening tools, including low negative predictive value and relatively high cost. Recently developed biomarkers such as FISH and improved imaging techniques, may help overcome current problems and provide improved screening and surveillance for esophageal cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19327567      PMCID: PMC3815691          DOI: 10.1016/j.gtc.2009.01.014

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  73 in total

1.  Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia.

Authors:  B J Reid; P L Blount; Z Feng; D S Levine
Journal:  Am J Gastroenterol       Date:  2000-11       Impact factor: 10.864

2.  Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation.

Authors:  V F Eckardt; G Kanzler; G Bernhard
Journal:  Am J Med       Date:  2001-07       Impact factor: 4.965

3.  Esophageal cancer: cases and causes (part I).

Authors:  R Lambert; P Hainaut
Journal:  Endoscopy       Date:  2007-06       Impact factor: 10.093

4.  Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma.

Authors:  N S Buttar; K K Wang; T J Sebo; D M Riehle; K K Krishnadath; L S Lutzke; M A Anderson; T M Petterson; L J Burgart
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

Review 5.  Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review.

Authors:  Gareth S Dulai; Sushovan Guha; Katherine L Kahn; Jeffrey Gornbein; Wilfred M Weinstein
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

6.  Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus.

Authors:  Benjamin Avidan; Amnon Sonnenberg; Thomas G Schnell; Stephen J Sontag
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

7.  Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma.

Authors:  A Sonnenberg; A Soni; R E Sampliner
Journal:  Aliment Pharmacol Ther       Date:  2002-01       Impact factor: 8.171

8.  Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study.

Authors:  C E Macdonald; A C Wicks; R J Playford
Journal:  BMJ       Date:  2000-11-18

9.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation.

Authors:  E Montgomery; M P Bronner; J R Goldblum; J K Greenson; M M Haber; J Hart; L W Lamps; G Y Lauwers; A J Lazenby; D N Lewin; M E Robert; A Y Toledano; Y Shyr; K Washington
Journal:  Hum Pathol       Date:  2001-04       Impact factor: 3.466

10.  Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota.

Authors:  M Conio; A J Cameron; Y Romero; C D Branch; C D Schleck; L J Burgart; A R Zinsmeister; L J Melton; G R Locke
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

View more
  6 in total

1.  Clinical evaluation of 4 types of microRNA in serum as biomarkers of esophageal squamous cell carcinoma.

Authors:  Kai Wang; Dongmei Chen; Yue Meng; Jianjun Xu; Qingyun Zhang
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

2.  Management of Barrett's oesophagus and intramucosal oesophageal cancer: a review of recent development.

Authors:  Shanmugarajah Rajendra; Prateek Sharma
Journal:  Therap Adv Gastroenterol       Date:  2012-09       Impact factor: 4.409

3.  Barrett's Esophagus.

Authors:  Shanmugarajah Rajendra; Prateek Sharma
Journal:  Curr Treat Options Gastroenterol       Date:  2014-06

4.  The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.

Authors:  Alvarez Hector; Elizabeth A Montgomery; Collins Karikari; Marcia Canto; Kerry B Dunbar; Jean S Wang; Georg Feldmann; Seung-Mo Hong; Michael C Haffner; Alan K Meeker; Sacha J Holland; Jiaxin Yu; Thilo J Heckrodt; Jing Zhang; Pingyu Ding; Dane Goff; Rajinder Singh; Juan Carlos Roa; Arivusudar Marimuthu; Gregory J Riggins; James R Eshleman; Barry D Nelkin; Akhilesh Pandey; Anirban Maitra
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

5.  ABL regulation by AXL promotes cisplatin resistance in esophageal cancer.

Authors:  Jun Hong; Dunfa Peng; Zheng Chen; Vikas Sehdev; Abbes Belkhiri
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 12.701

6.  1H-NMR based metabonomic profiling of human esophageal cancer tissue.

Authors:  Liang Wang; Jie Chen; Longqi Chen; Pengchi Deng; Qian Bu; Pu Xiang; Manli Li; Wenjie Lu; Youzhi Xu; Hongjun Lin; Tianming Wu; Huijuan Wang; Jing Hu; Xiaoni Shao; Xiaobo Cen; Ying-Lan Zhao
Journal:  Mol Cancer       Date:  2013-04-04       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.